Alliancebernstein L.P. Sells 443,597 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Alliancebernstein L.P. decreased its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,578,393 shares of the life sciences company's stock after selling 443,597 shares during the quarter. Alliancebernstein L.P. owned about 3.34% of Integra LifeSciences worth $58,478,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IART. Principal Financial Group Inc. lifted its holdings in shares of Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after purchasing an additional 63,266 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Integra LifeSciences by 824.5% during the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after purchasing an additional 99,685 shares during the last quarter. Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 53.9% during the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock valued at $11,115,000 after purchasing an additional 214,272 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Integra LifeSciences by 15.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after purchasing an additional 125,620 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Integra LifeSciences by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 39,638 shares of the life sciences company's stock worth $720,000 after acquiring an additional 22,334 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Stock Down 8.3 %

Shares of NASDAQ IART traded down $1.59 during mid-day trading on Thursday, reaching $17.60. 93,613 shares of the company traded hands, compared to its average volume of 1,045,768. The company's fifty day moving average is $22.63 and its two-hundred day moving average is $22.31. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $34.41. The stock has a market cap of $1.36 billion, a PE ratio of -197.76, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same quarter in the prior year, the company earned $0.89 EPS. The firm's revenue for the quarter was up 11.5% compared to the same quarter last year. On average, analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.